Substances · Benzodiazepines and thienodiazepines
Pyrazolam
- Preferred name
- Pyrazolam
- IUPAC name
- 8-bromo-1-methyl-6-pyridin-2-yl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
- Parent CAS number (reference)
- 39243-02-2
- Molecular formula
- C16H12BrN5
- Molecular weight
- 354.2 g/mol
- InChIKey
- BGRWSFIQQPVEML-UHFFFAOYSA-N
- PubChem
- CID 12562545
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
SH-I-04 Pyridinyl-bromazolam
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
Pyrazolam
Receptor Telemetry & Mechanism of Action
Pyridinyl-bromotriazolobenzodiazepine exhibiting preferential functional selectivity toward alpha2 and alpha3 GABA-A subunits over hypnotic alpha1 subunits.
Biotransformation & Active Metabolites
Excreted largely unchanged renally with minimal hepatic Phase I active metabolites.
Temporal Pharmacokinetics
Alpha2/Alpha3-Leaning Anxiolytic GABA-A PAM — 1 tablet = 1 mg lies cleanly in the functional anxiolytic range; distinguished from Bromazolam and Flualprazolam by minimal hepatic metabolism and noticeably lower alpha1 drowsiness at equivalent anxiolytic levels.
- Onset 15–35 min
- Peak Window 1–2.5 h
- Total Window 5–8 h
- Residual / Half-Life 4–10 h minimal metabolite tail
1 tablet = 1 mg lies cleanly in the functional anxiolytic range; distinguished from Bromazolam and Flualprazolam by minimal hepatic metabolism and noticeably lower alpha1 drowsiness at equivalent anxiolytic levels.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
0.5 mg
Subtle threshold receptor activity (Alpha2/Alpha3-Leaning Anxiolytic GABA-A PAM).
Minimal baseline autonomic shift.
0.5–1 mg
Mild, clear-headed expression of primary class profile.
Light somatic modulation.
1–2 mg
Full characteristic neurochemical and perceptual profile documented in literature.
Moderate somatic relaxation, ataxia, or autonomic tone depending on class.
2–3 mg
Pronounced intensity, cognitive/motor impairment, or deep immersion.
Marked somatic load and heightened adverse-event sensitivity.
4+ mg
Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.
High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.
Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.
Elevated Hazard — Avoid
Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.
Caution / Receptor Attenuation
CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.
Structural Isomer & Sibling Comparison
1 tablet = 1 mg lies cleanly in the functional anxiolytic range; distinguished from Bromazolam and Flualprazolam by minimal hepatic metabolism and noticeably lower alpha1 drowsiness at equivalent anxiolytic levels.
Physicochemical Stability & Storage
Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.
Store sealed in a cool, dry, light-protected container away from humidity.
Cross-Tolerance & Dependence Profile
Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.
Chemical Architecture & Structural Profile
Pyrazolam (8-bromo-1-methyl-6-pyridin-2-yl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a reference compound belonging to the Benzodiazepines and thienodiazepines class, characterized by the molecular formula C16H12BrN5 and a molar mass of 354.2 g/mol. The parent molecule is indexed under CAS registry number 39243-02-2 and in the NCBI PubChem database as CID 12562545 (Standard InChIKey: BGRWSFIQQPVEML-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Pyrazolam is indexed within the Benzodiazepines structural group. Toxicological notes (PsychonautWiki): low toxicity, potentially lethal when mixed with depressants like alcohol or opioids. Dependence liability (PsychonautWiki): extremely physically and psychologically addictive. Documented cross-tolerance class: benzodiazepines. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- EUDA / National Chemical & Controlled Substance Registry (IE) — National Regulatory Authority (IE) (2026-11-12)